In vitro susceptibility testing of Yersinia species to eight plant extracts and three natural antimicrobial agents

2012 ◽  
Vol 11 (42) ◽  
Author(s):  
Owhe-Ureghe
Keyword(s):  
Plant Extracts ◽  
Antimicrobial Agents ◽  
Susceptibility Testing ◽  
Natural Antimicrobial ◽  
In Vitro Susceptibility ◽  
Yersinia Species ◽  
In Vitro Susceptibility Testing

Infection of the Subcutis and Skin of Cats with Rapidly Growing Mycobacteria: A Review of Microbiological and Clinical Findings

2000 ◽  
Vol 2 (1) ◽  
pp. 35-48 ◽  
Author(s):  
R Malik ◽  
D I Wigney ◽  
D Dawson ◽  
P Martin ◽  
G B Hunt ◽  
...  
Keyword(s):  
Oral Therapy ◽  
Antimicrobial Agents ◽  
Susceptibility Testing ◽  
Inhibitory Concentration ◽  
Clinical Findings ◽  
Disc Diffusion ◽  
In Vitro Susceptibility ◽  
In Vitro Susceptibility Testing

Mycobacteria were isolated and characterised from 49 cats with extensive infections of the subcutis and skin. Cats were generally between 3 and 10 years of age, and female cats were markedly over-represented. All isolates were rapid-growers and identified as either Mycobacteria smegmatis (40 strains) or M fortuitum (nine strains). On the basis of Etest for minimum inhibitory concentration and/or disc diffusion susceptibility testing, all strains of M smegmatis were susceptible to trimethoprim while all strains of M fortuitum were resistant. M smegmatis strains were typically susceptible to doxycycline, gentamicin and fluoroquinolones but not clarithromycin. All M fortuitum strains were susceptible to fluoroquinolones, and often also susceptible to gentamicin, doxycycline and clarithromycin. Generally, M smegmatis strains were more susceptible to antimicrobial agents than M fortuitum strains. Treatment of mycobacterial panniculitis involves long courses of antimicrobial agents, typically of 3–6 months, chosen on the basis of in vitro susceptibility testing and often combined with extensive surgical debridement and wound reconstruction. These therapies will result in effective cure of the disease. One or a combination of doxycycline, ciprofloxacin/enrofloxacin or clarithromycin are the drugs of choice for long-term oral therapy.

scholarly journals Discovery of beta-lactamase CMY-10 inhibitors for combination therapy against multi-drug resistant Enterobacteriaceae

PLoS ONE ◽  
2021 ◽  
Vol 16 (1) ◽  
pp. e0244967
Author(s):  
Nousheen Parvaiz ◽  
Faisal Ahmad ◽  
Wenbo Yu ◽  
Alexander D. MacKerell ◽  
Syed Sikander Azam
Keyword(s):  
Combination Therapy ◽  
Antimicrobial Agents ◽  
Susceptibility Testing ◽  
Clinical Isolates ◽  
Drug Resistant ◽  
Activity Assay ◽  
Primary Resistance ◽  
In Vitro Susceptibility ◽  
In Vitro Susceptibility Testing

β-lactam antibiotics are the most widely used antimicrobial agents since the discovery of benzylpenicillin in the 1920s. Unfortunately, these life-saving antibiotics are vulnerable to inactivation by continuously evolving β-lactamase enzymes that are primary resistance determinants in multi-drug resistant pathogens. The current study exploits the strategy of combination therapeutics and aims at identifying novel β-lactamase inhibitors that can inactivate the β-lactamase enzyme of the pathogen while allowing the β-lactam antibiotic to act against its penicillin-binding protein target. Inhibitor discovery applied the Site-Identification by Ligand Competitive Saturation (SILCS) technology to map the functional group requirements of the β-lactamase CMY-10 and generate pharmacophore models of active site. SILCS-MC, Ligand-grid Free Energy (LGFE) analysis and Machine-learning based random-forest (RF) scoring methods were then used to screen and filter a library of 700,000 compounds. From the computational screens 74 compounds were subjected to experimental validation in which β-lactamase activity assay, in vitro susceptibility testing, and Scanning Electron Microscope (SEM) analysis were conducted to explore their antibacterial potential. Eleven compounds were identified as enhancers while 7 compounds were recognized as inhibitors of CMY-10. Of these, compound 11 showed promising activity in β-lactamase activity assay, in vitro susceptibility testing against ATCC strains (E. coli, E. cloacae, E. agglomerans, E. alvei) and MDR clinical isolates (E. cloacae, E. alvei and E. agglomerans), with synergistic assay indicating its potential as a β-lactam enhancer and β-lactamase inhibitor. Structural similarity search against the active compound 11 yielded 28 more compounds. The majority of these compounds also exhibited β-lactamase inhibition potential and antibacterial activity. The non-β-lactam-based β-lactamase inhibitors identified in the current study have the potential to be used in combination therapy with lactam-based antibiotics against MDR clinical isolates that have been found resistant against last-line antibiotics.

Sign in / Sign up

Export Citation Format

Share Document